Share-based Payment Arrangement, Expense of Acrivon Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acrivon Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,911,000, a 6.5% increase year-over-year.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $15,336,000, a 12% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,288,000, a 23% increase from 2023.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11,618,000, a 432% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,185,000, a 340% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Acrivon Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $15,336,000 $3,911,000 +$240,000 +6.5% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $15,096,000 $3,927,000 +$361,000 +10% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $14,735,000 $3,791,000 +$447,000 +13% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $14,288,000 $3,707,000 +$649,000 +21% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $13,639,000 $3,671,000 +$443,000 +14% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $13,196,000 $3,566,000 +$880,000 +33% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $12,316,000 $3,344,000 +$698,000 +26% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $11,618,000 $3,058,000 +$1,412,000 +86% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $10,206,000 $3,228,000 +$2,961,000 +1109% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $7,245,000 $2,686,000 +$2,453,000 +1053% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $4,792,000 $2,646,000 +$2,607,000 +6685% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $2,185,000 $1,646,000 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $267,000 +$240,000 +889% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $233,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $39,000 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q3 2021 $27,000 01 Jul 2021 30 Sep 2021 10-Q 15 Dec 2022 2022 Q3

Acrivon Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,288,000 +$2,670,000 +23% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $11,618,000 +$9,433,000 +432% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $2,185,000 +$1,688,000 +340% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $497,000 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.